CGRP inhibitors in Migraine - Competitive landscape, 2026

DelveInsight’s, “CGRP inhibitors in Migraine Competitive landscape 2026” report provides comprehensive insights about 5+ companies and 5+ drugs in CGRP inhibitors in Migraine  Competitive landscape. It covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

Geography Covered

• • Global coverage

CGRP inhibitors in Migraine Disease Understanding

CGRP inhibitors in Migraine Overview

Migraine is a complex, chronic neurological disorder characterized by recurrent episodes of moderate to severe headache, typically unilateral and pulsating in nature, lasting anywhere from 4 to 72 hours. It is frequently accompanied by debilitating associated symptoms including nausea, vomiting, and heightened sensitivity to light (photophobia) and sound (phonophobia). Migraine attacks are often preceded by a prodromal phase and, in approximately one-third of patients, by an aura — transient neurological disturbances involving visual, sensory, or speech disturbances. Globally, migraine ranks among the leading causes of disability, disproportionately affecting women of reproductive age and imposing a substantial burden on quality of life, productivity, and healthcare systems.

The pathophysiology of migraine is multifaceted, involving a complex interplay between cortical, subcortical, and brainstem systems. Central to the process is cortical spreading depression (CSD) — a slowly propagating wave of neuronal and glial depolarization that underlies the migraine aura and is thought to trigger downstream activation of the trigeminovascular system. This activation leads to the release of inflammatory neuropeptides into the meningeal vasculature, producing neurogenic inflammation and sensitization of peripheral and central pain pathways. The trigeminal nucleus caudalis, a key relay station in the brainstem, plays a pivotal role in amplifying and transmitting these pain signals, ultimately giving rise to the characteristic headache and its associated features.

Calcitonin gene-related peptide (CGRP) is a 37-amino acid neuropeptide expressed in trigeminal sensory neurons and recognized as a central mediator of migraine pathogenesis. During an attack, CGRP is released from trigeminal nerve terminals into the cranial circulation, acting as a potent vasodilator and pro-inflammatory agent that drives meningeal vessel dilation and neurogenic inflammation. Plasma and cerebrospinal fluid levels of CGRP are consistently elevated during acute migraine episodes and normalize following successful treatment, firmly establishing it as a key driver of migraine pain rather than merely a secondary phenomenon.

CGRP inhibitors work by interrupting the CGRP signaling pathway at one of two points — either neutralizing the peptide itself or blocking its receptor — thereby halting the cascade of vasodilation, neurogenic inflammation, and central sensitization that sustains a migraine attack. Monoclonal antibodies targeting CGRP or its receptor provide sustained pathway blockade over weeks to months, making them effective for preventive use in patients with frequent or chronic migraine. Small molecule receptor antagonists, on the other hand, offer a rapid-onset oral option for acute treatment, acting selectively without vasoconstrictive effects and broadening the eligible patient population to include those with cardiovascular comorbidities who cannot tolerate conventional therapies.

CGRP inhibitors in Migraine Pipeline Report Highlights

• • In March 2026, Tonix Pharmaceuticals Holding Corp. announced the dosing of the first participant in a Phase I investigator-initiated study evaluating TNX-1900 (intranasal potentiated oxytocin) for the treatment of migraine and craniofacial pain. Conducted in collaboration with Erasmus University Medical Center, the study is designed to investigate the therapeutic potential of TNX-1900 using Laser Speckle Contrast Imaging (LSCI) technology to assess dermal blood flow responses. The company highlighted that the trial aims to further support TNX-1900 as a potential non-opioid therapeutic approach for migraine and craniofacial pain disorders.
• • In August 2025, Teva Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved AJOVY for the preventive treatment of episodic migraine in children and adolescent patients aged 6-17 years who weigh 45 kilograms (99 pounds) or more. With this approval, AJOVY becomes the first and only calcitonin gene-related peptide (CGRP) antagonist indicated for the preventive treatment of episodic migraine in pediatric patients and migraine in adults, marking a meaningful advancement in expanding preventive treatment options for those living with migraine.
• • In June 2025, AbbVie announced positive topline results from its Phase 3 TEMPLE multicenter, randomized, double-blind, head-to-head study evaluating the tolerability, safety and efficacy of atogepant (QULIPTA® / AQUIPTA®, 60 mg once daily) compared to the highest tolerated dose of topiramate (50, 75 or 100 mg/day) in adult patients with a history of four or more migraine days per month.

CGRP inhibitors in Migraine: Company and Product Profiles (Marketed Therapies)

1. Company Overview: Pfizer

Pfizer is a global biopharmaceutical company headquartered in New York City that focuses on the discovery, development, manufacturing, and commercialization of medicines and vaccines across multiple therapeutic areas. Founded in 1849, the company has built a broad portfolio spanning oncology, immunology, cardiology, inflammation, rare diseases, vaccines, and neuroscience. Pfizer is widely recognized for developing innovative therapies and advancing research through collaborations, acquisitions, and extensive clinical development programs worldwide. The company has also played a major role in global public health through the development of vaccines and targeted treatments for various diseases. Pfizer has focused on advancing CGRP-targeted therapies for migraine by developing innovative gepant-based treatments, including oral and intranasal CGRP receptor antagonists designed for the acute and preventive management of migraine.

Product Description: Zavzpret

Zavegepant, marketed as Zavzpret, is a third-generation, high-affinity calcitonin gene-related peptide (CGRP) receptor antagonist developed for the acute treatment of migraine with or without aura in adults. The drug was approved by the U.S. FDA in March 2023 as the first and only intranasal CGRP receptor antagonist for migraine treatment. Administered as a 10 mg nasal spray, Zavegepant was designed to provide a non-oral and fast-acting treatment option, particularly beneficial for patients experiencing nausea or difficulty swallowing during migraine attacks. In pivotal clinical studies, the drug demonstrated statistically significant superiority over placebo in achieving pain freedom and relief from the most bothersome migraine symptom at two hours post-dose, with pain relief observed as early as 15 minutes in some patients. This drug is the only CGRP receptor antagonist in clinical development with both intranasal and oral formulations.

2. Company Overview: H. Lundbeck A/S

H. Lundbeck A/S is a global biopharmaceutical company headquartered in Copenhagen that specializes in the research, development, manufacturing, and commercialization of therapies for brain diseases and neurological disorders. Founded in 1915, the company has more than 70 years of expertise in neuroscience and focuses on conditions such as migraine, depression, schizophrenia, Parkinson’s disease, epilepsy, and Alzheimer’s disease. The company is recognized for its strong emphasis on brain health innovation and has developed several targeted therapies aimed at improving the lives of patients with neurological and psychiatric disorders worldwide.

Product Description: VYEPTI

Eptinezumab, marketed as VYEPTI, is a humanized monoclonal antibody developed by Lundbeck for the preventive treatment of migraine in adults. The drug targets the calcitonin gene-related peptide (CGRP) ligand, helping prevent migraine attacks by blocking CGRP signaling. Approved by the U.S. FDA in 2020, Eptinezumab is administered as an intravenous infusion every three months and has demonstrated significant reductions in monthly migraine days in clinical studies. The therapy has now been approved in more than 30 countries worldwide, and Lundbeck has further expanded its global regulatory efforts by filing marketing authorization applications across key Asian markets, including China, Japan, and South Korea, supported by Phase III SUNRISE trial data in Asian migraine patients.

CGRP inhibitors in Migraine: Company and Product Profiles (Pipeline Therapies)

1. Company Overview: Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of therapies for central nervous system disorders, immunology, infectious diseases, and rare disorders. Headquartered in Chatham, the company is particularly recognized for its research in neurological and pain-related conditions, including migraine, fibromyalgia, PTSD, and long COVID. Tonix is advancing a diversified pipeline of investigational therapies designed to address unmet medical needs through innovative therapeutic approaches and novel drug delivery technologies. The company is actively advancing migraine research through its investigational candidate TNX-1900, an intranasal potentiated oxytocin therapy designed to inhibit the release of calcitonin gene-related peptide (CGRP), a key neuropeptide involved in migraine pathophysiology. 

Product Description: TNX-1900

TNX-1900 is an investigational intranasal potentiated oxytocin therapy being developed for the treatment of migraine and craniofacial pain. The drug is a proprietary drug-device combination product designed to deliver oxytocin directly into the nasal cavity, targeting the trigeminal system involved in migraine pathophysiology. Unlike conventional CGRP receptor antagonists or anti-CGRP antibodies, TNX-1900 works by inhibiting the release of calcitonin gene-related peptide (CGRP) from trigeminal neurons, thereby reducing pain signal transmission. The formulation also contains magnesium, which enhances oxytocin receptor binding and may contribute additional inhibitory effects on trigeminal nerve activity. Targeted intranasal delivery is intended to provide localized action with lower systemic exposure, potentially reducing off-target effects associated with systemic CGRP inhibition. As per latest press release, In March 2026, Tonix Pharmaceuticals Holding Corp.  announced that the first participant has been dosed in a Phase I investigator-initiated study to evaluate the effect of TNX-1900 (intranasal potentiated oxytocin) on trigeminal nerve-mediated vasodilation of the forehead using capsaicin as well as electrical stimulation, a model for trigeminal neurovascular reactivity, in healthy female human volunteers. Dr. Antoinette Maassen van den Brink, Professor of Neurovascular Pharmacology, Erasmus University Medical Center, is serving as principal investigator and sponsor for the study in a collaborative research agreement with Tonix. Currently, the drug is in Phase I stage of its development for the treatment of Migraine.

Further product details are provided in the report……..

CGRP inhibitors in Migraine Analytical Perspective by DelveInsight

• In-depth Commercial Assessment: CGRP inhibitors in Migraine Collaboration Analysis by Companies

The Report provides in-depth commercial assessment of drugs that have been included, which comprises collaboration, agreement, licensing and acquisition – deals values trends. The sub-segmentation is described in the report which provide company-company collaboration (licensing/partnering), company academic collaboration and acquisition analysis in tabulated form.

• CGRP inhibitors in Migraine Competitive Landscape

The report comprises of comparative assessment of Companies (by therapy, development stage, and technology).

CGRP inhibitors in Migraine Report Assessment

• Company Analysis

• • Therapeutic Assessment
• • Pipeline Assessment
• • Inactive drugs assessment
• • Unmet Needs

Key Questions Answered In The CGRP inhibitors in Migraine Competitive Landscape Report

Current Treatment Scenario and Emerging Therapies:

• • How many companies are developing CGRP inhibitors in Migraine drugs?
• • How many CGRP inhibitors in Migraine drugs are developed by each company?
• • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of CGRP inhibitors in Migraine?
• • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the CGRP inhibitors in Migraine therapeutics?
• • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• • What are the clinical studies going on for CGRP inhibitors in Migraine and their status?
• • What are the key designations that have been granted to the emerging and approved drugs?

CGRP inhibitors in Migraine Key Companies

• • Pfizer
• • H. Lundbeck A/S
• • Eli Lilly and Company
• • Tonix Pharmaceuticals Holding Corp.

CGRP inhibitors in Migraine Key Products

• • Zavegepant
• • Eptinezumab
• • Galcanezumab
• • TNX-1900